Abstract | PURPOSE: PATIENTS AND METHODS: From 1984 until December 1992, 91 patients, median age 56 years (range 28 to 77 years), with clinical stage I-II low-grade lymphoma were treated. No patients were excluded on the basis of age or organ function. RESULTS: A complete response was attained in 99% of evaluable patients. Treatment-related toxicity was mild, and no deaths occurred during therapy. With a median follow-up of 60 months, there have been only 16 relapses. The actuarial freedom from relapse rate at five years is 82% (95% confidence interval 71% to 89%) and at 10 years is 73%. At five years the overall survival rate is 90% (95% confidence interval 81% to 95%) and at ten years it is 82%. Of the clinical features examined, only older age (> 56 years; p = 0.07) was associated with shorter survival. No features examined were predictive of disease relapse. CONCLUSION: The combination of IF radiation and risk-adapted COP/ CHOP-Bleo chemotherapy is well-tolerated, produces a very high rate of complete remission, and with a median follow-up of five years, has produced lower rates of relapse and better overall survival than has been reported for IF radiation alone in patients with clinically-staged I-II low-grade lymphoma.
|
Authors | J F Seymour, P McLaughlin, L M Fuller, F B Hagemeister, M Hess, F Swan, J Romaguera, M A Rodriguez, P Besa, J Cox, F Cabanillas |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 7
Issue 2
Pg. 157-63
(Feb 1996)
ISSN: 0923-7534 [Print] England |
PMID | 8777172
(Publication Type: Clinical Trial, Journal Article)
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Humans
- Lymphoma, Non-Hodgkin
(mortality, radiotherapy, therapy)
- Male
- Middle Aged
- Prognosis
- Prospective Studies
- Radiotherapy Dosage
- Remission Induction
|